Birth Defects

0
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

M&
Merck & Co.RAHWAY, NJ
1 program
The Ribavirin Pregnancy RegistryN/A
Teva
TevaIsrael - Petach Tikva
1 program
The Ribavirin Pregnancy RegistryN/A1 trial
Active Trials
NCT00114712Terminated477Est. Nov 2020
UP
UCB PharmaBelgium - Brussels
1 program
UCB Antiepileptic Drugs (AED) Pregnancy Registry (Formerly the Keppra® Pregnancy Registry)N/A1 trial
Active Trials
NCT00345475Completed516Est. May 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
UCB PharmaUCB Antiepileptic Drugs (AED) Pregnancy Registry (Formerly the Keppra® Pregnancy Registry)
TevaThe Ribavirin Pregnancy Registry

Clinical Trials (2)

Total enrollment: 993 patients across 2 trials

NCT00345475UCB PharmaUCB Antiepileptic Drugs (AED) Pregnancy Registry (Formerly the Keppra® Pregnancy Registry)

UCB Antiepileptic Drugs (AED) Pregnancy Registry (Formerly the Keppra® Pregnancy Registry)

Start: Dec 2004Est. completion: May 2016516 patients
N/ACompleted
NCT00114712TevaThe Ribavirin Pregnancy Registry

The Ribavirin Pregnancy Registry

Start: Jan 2004Est. completion: Nov 2020477 patients
N/ATerminated

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space